JP2024538117A5 - - Google Patents

Info

Publication number
JP2024538117A5
JP2024538117A5 JP2024522406A JP2024522406A JP2024538117A5 JP 2024538117 A5 JP2024538117 A5 JP 2024538117A5 JP 2024522406 A JP2024522406 A JP 2024522406A JP 2024522406 A JP2024522406 A JP 2024522406A JP 2024538117 A5 JP2024538117 A5 JP 2024538117A5
Authority
JP
Japan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
pharmaceutical product
product according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024522406A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538117A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/046291 external-priority patent/WO2023064282A1/en
Publication of JP2024538117A publication Critical patent/JP2024538117A/ja
Publication of JP2024538117A5 publication Critical patent/JP2024538117A5/ja
Pending legal-status Critical Current

Links

JP2024522406A 2021-10-13 2022-10-11 Wee1阻害剤と抗cd47抗体との組み合わせ。 Pending JP2024538117A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163262466P 2021-10-13 2021-10-13
US63/262,466 2021-10-13
PCT/US2022/046291 WO2023064282A1 (en) 2021-10-13 2022-10-11 Combinations of wee 1 inhibitors and anti-cd47 antibodies.

Publications (2)

Publication Number Publication Date
JP2024538117A JP2024538117A (ja) 2024-10-18
JP2024538117A5 true JP2024538117A5 (cg-RX-API-DMAC7.html) 2025-10-22

Family

ID=85987727

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024522406A Pending JP2024538117A (ja) 2021-10-13 2022-10-11 Wee1阻害剤と抗cd47抗体との組み合わせ。

Country Status (6)

Country Link
US (1) US20240261295A1 (cg-RX-API-DMAC7.html)
EP (1) EP4415721A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024538117A (cg-RX-API-DMAC7.html)
CN (1) CN118139625A (cg-RX-API-DMAC7.html)
TW (1) TW202320758A (cg-RX-API-DMAC7.html)
WO (1) WO2023064282A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021097139A1 (en) 2019-11-15 2021-05-20 Recurium Ip Holdings, Llc Chiral synthesis of a tertiary alcohol
KR20230038523A (ko) 2020-07-09 2023-03-20 리커리엄 아이피 홀딩스, 엘엘씨 Wee1 억제제의 염 및 형태
JP2024526203A (ja) * 2021-06-23 2024-07-17 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Wee1阻害剤、及びがんを治療するための方法
WO2023217201A2 (zh) * 2022-05-10 2023-11-16 杭州德睿智药科技有限公司 作为Wee1抑制剂的新型嘧啶并杂环类新化合物及其应用
WO2025193930A1 (en) * 2024-03-14 2025-09-18 Zeno Management, Inc. Wee1 inhibitor combination therapy
WO2026082160A1 (zh) * 2024-10-18 2026-04-23 上海瑛派药业有限公司 Wee1蛋白降解剂及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2905418C (en) * 2013-03-13 2023-03-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
WO2020198734A1 (en) * 2019-03-28 2020-10-01 The Penn State Research Foundation Methods, compositions relating to treatment of cancer
PH12022550835A1 (en) * 2019-10-18 2023-07-03 Forty Seven Inc Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia

Similar Documents

Publication Publication Date Title
JP2021530451A5 (cg-RX-API-DMAC7.html)
JP2021184721A5 (cg-RX-API-DMAC7.html)
JP2022512900A5 (cg-RX-API-DMAC7.html)
JP2021530453A5 (cg-RX-API-DMAC7.html)
JP2023506530A5 (cg-RX-API-DMAC7.html)
JP2017529838A5 (cg-RX-API-DMAC7.html)
JP2021514664A5 (cg-RX-API-DMAC7.html)
JP2022166014A5 (cg-RX-API-DMAC7.html)
JP2024020298A5 (cg-RX-API-DMAC7.html)
JP2021525248A5 (cg-RX-API-DMAC7.html)
JP2005530736A5 (cg-RX-API-DMAC7.html)
JP2018536636A5 (cg-RX-API-DMAC7.html)
JP2020510662A5 (cg-RX-API-DMAC7.html)
CN114555123B (zh) 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法
JP2010540556A5 (cg-RX-API-DMAC7.html)
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP2024515591A5 (cg-RX-API-DMAC7.html)
JP2020515578A5 (cg-RX-API-DMAC7.html)
JP2022511394A5 (cg-RX-API-DMAC7.html)
JP2017031160A5 (cg-RX-API-DMAC7.html)
JP2021073250A5 (cg-RX-API-DMAC7.html)
JP2021530487A5 (cg-RX-API-DMAC7.html)
JP2009502743A5 (cg-RX-API-DMAC7.html)
JP2017515792A5 (cg-RX-API-DMAC7.html)
JP2016166203A5 (cg-RX-API-DMAC7.html)